Led · Series F · Apr 2026

VAST Data offers an AI operating system that unifies foundational data, compute services, and agentic execution into a single scalable software infrastructure stack. Its platform is positioned to enable organizations to deploy and coordinate AI agents, reason over real-time data, and automate complex workflows at scale. The company is led by founder and CEO Renen Hallak and is based in New York City. With the announced Series F, VAST reached an implied valuation of $30 billion after raising approximately $1 billion in primary and secondary capital. VAST intends to use the proceeds to consolidate its position, accelerate global growth, and pursue strategic transactions to expand its technology footprint and partnerships. The article does not disclose revenue, user, or other operating metrics.

Participated · Equity · Apr 2026

Founded in 2023 by chef Thomas Straker and Toby Hopkinson, All Things began as a viral social series and consumer brand and has expanded beyond butter into cottage cheese and other dairy formats. The brand's social content has amassed over 1 billion views and more than 5 million followers, helping it connect with a younger, food-loving audience; over 50% of its cottage cheese buyers are under 45. Commercially, All Things has distribution in over 2,500 stores including Sainsbury’s, Waitrose, Morrisons, Ocado, Co-op and others, sold 250 tonnes of butter in the past year, and its cottage cheese range became a market leader within three months. The company has launched in the Middle East and plans a national US retailer launch in September, with an upcoming listing at Tesco and further global expansion planned. All Things is broadening its product portfolio supported by a new product development pipeline and intends to use the recent funding to strengthen supply-chain partnerships and begin vertical integration to scale production.

Participated · Series A · Mar 2026

Vima Therapeutics is a Cambridge, Massachusetts–based clinical-stage biotechnology company focused on addressing movement disorders by targeting their underlying biology. Its lead asset, VIM0423, is a once-daily oral compound designed to selectively modulate muscarinic cholinergic receptors to correct the dopamine–acetylcholine imbalance implicated in dystonia and Parkinson’s disease. A two-part Phase 1 study showed VIM0423 was well tolerated, exceeded target exposure levels, and demonstrated a favorable safety profile over 28 days in healthy volunteers and dystonia patients. The company has now dosed the first participant in a Phase 2 trial for isolated dystonia and plans to start a parallel Phase 2 study in Parkinson’s disease in mid-2026, with topline data from both studies expected in the first half of 2027. VIM0423 holds FDA Fast Track designation for isolated dystonia, which affects more than 160,000 people in the U.S. Financially, Vima has secured up to $100 million through its Series A financing, providing runway to complete both Phase 2 trials. Founded and incubated at Atlas Venture by physicians and scientists specializing in movement disorders, the company leverages an exclusive worldwide license from Children’s Mercy for certain antimuscarinic compounds.

Participated · Seed · Mar 2026

ZyG builds ZyG OS, an end-to-end platform that leverages agentic AI infrastructure to identify products with scale potential and execute functions across brand building, store creation, creative generation, user acquisition, conversion optimization, retention and logistics. The company partners with online brands that have initial traction and that pass its Product Market Fit test and high ZyG Score to predict scale potential. ZyG says its platform removes operational and data complexity and the financial risk of scaling so founders can focus on product development. The founding team includes the creators of ironSource and three leading AI experts from an Israeli cyber unit, combining commerce and AI expertise. ZyG also offers financing capabilities as part of its platform to help brands scale. The company is headquartered in Tel Aviv and plans to use the Series A proceeds to further develop and expand its agentic operating system for eCommerce scale.

Participated · Series B · Nov 2025

Founded in 2020, Numeric provides a connected finance operations platform that now spans Close Management, Analytics, and a newly launched Cash Management module. The software combines AI pattern recognition, deterministic code, and human review to automate previously manual accounting tasks, delivering a 90%+ auto-match rate for cash reconciliation versus sub-30% industry norms. Early customers such as Brex, Public.com and Clipboard Health report eliminating multiple days of monthly reconciliation work. Management positions the company as the ‘connected platform for finance operations,’ aiming to release additional workflow products through 2026-2027. Numeric operates from hubs in San Francisco, New York and London. To date the startup has raised $89 million in venture funding, which is being used to accelerate product expansion and platform development.